46 results about "Antipsychotic" patented technology

Methods of treating headache with antipsychotics are provided. A kit for treating headache is also provided, comprising an antipsychotic and a device for rapid delivery of the antipsychotic.

The present invention relates to the compound of formula

which is 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide, and to pharmaceutically acceptable acid addition salts thereof. It has been found that the compound is useful for the treatment or prevention of Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, ADHD (attention deficit hyper-activity disorder), drug addiction to amphetamines, cocaine, opioids, ethanol, nicotine, or cannabinoids, or for the treatment of asthma, allergic responses, hypoxia, ischemia, seizure, substance abuse, or for use as muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardioprotective agents.

Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amounts of one of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.

The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an antipsychotic or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In some embodiments, the methods and the compositions are for treating one or more positive and/or negative symptoms, as well as cognitive impairment, associated with schizophrenia or bipolar disorder (in particular, mania).

The invention relates to a synthesis method for 2-methoxyl-4-amino-5-ethylsulfonylbenzoic acid which is an important immediate for antipsychotics Amisulpride. The method uses 2-methoxyl-4-methyl anthranilate as raw material, and carries out amino protection, sulphurization, deamination protection, chloridization, reduction, thylization, esterolysis and crystallization, and then the 2-methoxyl-4-amine-5-ethylsulfonylbenzoic acid is prepared. The method uses common reagents with easy obtainment as reaction mediums, the reaction condition is high, and the prepared product has the advantages of high purity and high yield, and is suitable for industrialization production.

The present invention relates to a synergistic combination of an alpha7 (α7) nicotinic agonist and an antipsychotic agent.

The invention relates to a traditional Chinese medicine for treating schizophrenia and treating the side effect caused by antipsychotics and a preparation method thereof. The traditional Chinese medicine comprises the following raw medicines according to the proportion by weight: 10-17 ophiopogon roots, 7-14 medlar, 3-10 earthworms, 10-18 kudzu roots, 3-10 arillus longan, 7-14 lycopodium calvatum, 4-11 lotus leaf, 7-14 flos albiziae, 3-10 chrysoidine, 4-11 dates, 4-14 grass-leaved sweetflag, 4-11 radix curcumae and 7-14 liquorice. The dosage form comprises granules, sirup, tablets, capsules and oral liquid. The preparation method is as follows: adding water to boil to obtain liquid medicine, concentrating, filtering, adding antiseptic, subpackaging and sterilizing to obtain the oral liquid. The traditional Chinese medicine has the functions of nourishing Yin and clearing away the heart fire, tonifying the kidney and the brain as well as promoting blood circulation and removing obstruction in channels and the advantages of low cost, remarkable curative effect and no side effect, thereby achieving the aims of mainly treating muffing, fremitus, lags in response, witless expression, retardation of thinking, achexia, fidgety and confusion, talk nonsense, uncommunication, hygrostomia and indifference of patients suffering from schizophrenia, improving the memory impairment, promoting the recovery of psychopathy and preventing or reducing the recrudescency of psychopathy.

The present invention relates to compounds of formulae IA and IB

wherein

• R¹ and R² are each independently lower alkyl or —(CH₂)_m—O-lower alkyl, or together with the N atom to which they are attached form a heterocyclic ring;
• R³ is hydrogen or lower alkyl;
• R⁴ is lower alkyl; hetaryl is 3H-imidazole-2,4-diyl or 1H-pyrazole-1,4-diyl; n is 1 or 2; and m is 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. These compounds may be used for the treatment of Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, ADHD, drug addiction, such as amphetamine, cocaine, opioids, ethanol, nicotine, cannabinoids, or for the treatment of asthma, allergic responses, hypoxia, ischaemia, seizure and substance abuse, or for use as sedatives, muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardiaprotective agents for coronary artery disease and heart failure.

The invention discloses a high-dispersity composition of low-dose drugs and a preparation method of the high-dispersity composition, aiming to solve the problem that existing preparation methods for the low-dose drugs cannot meet requirements on content uniformity and influences of parameter change amplification in the production process on physicochemical properties of the low-dose drugs are remarkable. The high-dispersity composition and the preparation method thereof have the advantages that the low-dose drugs are prepared by the twin-screw extrusion technology for the first time; Vitamin Danalogue drugs, glucocorticoid drugs, antipsychotics, antipyretic and analgesic drugs and other low-dose drugs are screened as research objects; preparation of solid preparations through a twin-screwextruder is studied deeply; the content uniformity meets requirements of the pharmacopeia.

The present invention comprises methods and pharmaceutical compositions for intranasal delivery of effective amounts of DFO directly to the CNS, in particular the brain treatments that inhibit GSK3b in patients with psychiatric disorders including, but not limited to, bipolar disorder, depression, ADHD and schizophrenia. In addition a treatment composition is disclosed which comprises DFO and in certain embodiments combines DFO with one or more of the psychotropic drug types, i.e., antipsychotics, mood stabilizers and antidepressants. Moreover, a treatment for treating impairment of neural plasticity through inhibition of GSK3b is provided as well as prevention of apoptosis of cells through inhibition of GSK3b.

A method of humanely incapacitating or immobilizing a human or animal by providing a formulation including a cannabinoid rendering a recipient incapacitated or immobilized within a short period of time, and a delivery means which doses the recipient with the formulation resulting in a tetrahydrocannabinol blood level of above at least approximately 1-250 milligrams per milliliter of whole blood for incapacitation, or at least approximately 250-500 milligrams per milliliter of whole blood immobilization, and below a dosage which causes irreparable harm to or the death of the recipient. Providing a delivery means to induce an incapacitating or immobilizing dose at a distance. Providing a formulation including an antipsychotic to prevent or mitigate any violent psychosis of the recipient. Providing a formulation which induces a lethal cannabinoid blood level in the recipient which causes the death of the recipient within a humane period of time after formulation administration.

The present invention relates to a novel salt of (3aR,4S,7R,7aS)-2-[((1R,2R)-2-{[4-(1,2-benzisothiazol-3-yl)-piperazin-1-yl]methyl}cyclohexyl)methyl]hexahydro-1H-4,7-methanisoindol-1,3-dione and hydrates thereof, to methods for preparing the novel salt and its hydrates. In one aspect, the present invention provides a compound which is lurasidone dihydrochloride. In another aspect, the present invention provides a process for preparation of lurasidone dihydrochloride comprising: (i) mixing lurasidone free base in an organic solvent system; (ii) subjecting step (i) mixture to acid proton source; and (iii) isolating compound of lurasidone dihydrochloride.

The present invention relates to a pharmaceutical composition comprising an antipsychotic in combination with an anti-inflammatory agent, and to the use thereof in the treatment of psychotic disorder, and in particular, of schizophrenia.

The present invention relates to compounds of the general formula

wherein

• R¹ is cycloalkyl, substituted by OR or is 2-(7-oxa-bicyclo[2.2.1]hept-1-yl)-ethyl; R is hydrogen, lower alkyl or C(O)-lower alkyl; X is —CHR′—; and R′ is hydrogen or lower alkyl; and pharmaceutically acceptable acid addition salts, optically pure enantiomeres, racemates or diastereomeric mixtures thereof for the treatment of Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, ADHD, drug addiction, such as amphetamine, cocaine, opioids, ethanol, nicotine, cannabinoids, or for the treatment of asthma, allergic responses, hypoxia, ischaemia, seizure and substance abuse, or for use as sedatives, muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardiaprotective agents for coronary artery disease and heart failure.